Oxford and Moderna receive approval for Phase 1 trial of mRNA vaccine to prevent Lynch syndrome cancers
Solid neighbourhood-bakery energy. Trustworthy and warm.
Summary
The INTERCEPT-Lynch trial, a Phase 1 study funded by Moderna and sponsored by the University of Oxford, has received regulatory approval from the MHRA to begin testing a novel mRNA vaccine aimed at preventing cancers associated with Lynch syndrome. The trial is expected to start recruiting participants this summer and represents a collaboration between Oxford and Moderna to advance mRNA technology for cancer prevention. Led by Professor David Church, the study targets Lynch syndrome, a genetic condition that significantly increases cancer risk.
Key quotes
· 3 pulledPhase 1 of the INTERCEPT-Lynch trial... has received authorisation from the Medicines and Healthcare products Regulatory Agency and is expected to begin recruiting participants this summer.
The trial forms part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention.
Led by Professor David Church, Cancer Research UK Senior Cancer Research Fellow in the University of Oxford
You might also wanna read
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago
Scientists Develop Universal Cancer Vaccine Using mRNA Technology
Scientists have developed a 'universal cancer vaccine' using mRNA technology that can train the immune system to target any type of cancer,
newatlas.com·10mo ago
FDA Issues Refusal-to-File Letter to Moderna for mRNA Influenza Vaccine
The article criticizes the FDA's recent actions under the new administration, particularly focusing on a Refusal-to-File (RTF) letter issued
marginalrevolution.com·3mo ago
FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for trea
FDA·1mo ago
Moderna's Post-Pandemic Crisis: From Vaccine Success to Corporate Challenges
The article examines Moderna's current crisis despite its success with the COVID-19 vaccine. After achieving a 95% effective vaccine and mas
statnews.com·7mo ago
Long-term HPV vaccine effectiveness study shows stable protection against targeted virus types in Danish women vaccinated as girls
This study examines the long-term effectiveness of HPV vaccination in Danish women who received the 4-valent HPV vaccine as girls in 2008. T
eurosurveillance.org·5mo ago